Philip Morris faces a more complicated shareholder outlook as nicotine-pouch competition intensifies despite healthy U.S. demand. ZYN shipment volume grew 4.2% year over year in Q3, while Philip Morris is increasing investment, expanding formats and adjusting prices to defend share. x.com 

Turning Point Brands looks extremely interesting after falling about 60% from its highs, as it has become almost a pure play on nicotine pouches over the past two years. The new CEO may kitchen-sink results and the chart is unattractive, but betting on a materially lower price before upcoming catalysts play out looks increasingly poor. x.com 

Big Tobacco remains attractive because scale lowers unit costs and nicotine substitution can shift consumption beyond cigarettes. Cigarettes are homogeneous, so volume lowers costs; Sweden's shift to snus and nicotine pouches shows where consumption can move. The screen ranks tobacco among the strongest subsectors on fundamentals and market pricing. x.com  x.com  x.com  x.com 

Philip Morris is collecting the inheritance as nicotine moves from cigarettes to smoke-free products, after choosing a decade ago to replace its own core business. Smoke-free is now 40% of revenue, ZYN and IQOS grow 20%+ a year, and each smoke-free pack brings 2.5 times a cigarette's revenue. Sweden shows the path: under 5% of Swedes smoke daily after switching to snus and pouches. The $16B Swedish Match deal in 2022, called overpriced, made ZYN America's fastest-growing oral tobacco product. … Show more

British American Tobacco carries cannabis optionality that few big companies admit to, and Big Tobacco will lean into cannabis hard rather than pull back. BAT describes a "foothold in the cannabis space" that is "several years away from being a meaningful contributor". @UseThouBrain, in the post being answered, backs Organigram on the view that BAT's idea of meaningful means billions, backed by patent-pending non-combustible IP; that is a different bet, far down the field, but not a bad one. … Show more

Safe-haven stocks such as Altria, Philip Morris, Starbucks, Cboe, CAVA and Costco deserve attention in this market; they are on fire this week. Walmart, Coca-Cola, Apollo, Procter & Gamble and Visa are also showing strong setups. x.com 

Philip Morris offers profits outside everybody's favorite ten hyperscale stocks. On a walk around New York's East Village, literally every young woman seemed to be smoking a cigarette, Midwestern transplants as well as alternative crowds. Per Threadguy, the stock is quietly at all-time highs near $194 as vaping became embarrassing and Zyn took over. x.com 

British American Tobacco is a cigarette turnaround story nobody is talking about, with the stock up 100% in 18 months while paying a 6-10% dividend. x.com 

Altria, Johnson & Johnson, Waste Management, TJX, Linde, Costco and Quest Diagnostics add defense to a portfolio, scoring highest among S&P 500 stocks on an antifragility screen of low volatility, strong free cash flow, minimal debt and stable earnings. All are also trending up this year, with momentum scores above 75; Altria scores 100 on antifragility and J&J 99. x.com 

Emerging-market nicotine names are an overlooked way to play smokers switching to pouches, often at a fraction of their parents' multiples. RLX Technology, China's vape leader turning to pouches, holds about $2.25B of net cash against a $2.6B market cap, grew 2025 revenue 44%, launched AirPouch and has an explicit M&A strategy. Sampoerna, 92.5% owned by Philip Morris and Indonesia's largest tobacco company at 34.9% share, sells ZYN and its own Shiro pouches and hosts PMI's ASEAN smoke-free hub. … Show more